Search research articles
Contact Us
Filters
Showing results (381-390 of 404) with videos related to
Page
of 41
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Immunotherapy
|
October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
Melissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Tumori
|
May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study
Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Minerva Urology and Nephrology
|
June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
Pasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Therapeutic Advances in Medical Oncology
|
May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancers
|
January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Page
of 41
Search research articles
Search
Showing results (381-390 of 404) with videos related to
Sort By:
Page
of 41
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Philipp Mandel, Daniel Groener, Giulia Follacchio, et al.
European Urology Focus
|
July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Immunotherapy
|
October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
Melissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.
Tumori
|
May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study
Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Minerva Urology and Nephrology
|
June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
Pasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Therapeutic Advances in Medical Oncology
|
May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancers
|
January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Page
of 41